Latest News and Events

July 2019

iPharma logo

Nanomerics’ CEO Andreas Schatzlein to presesnt key note at the 3rd Global Pharmaceutical Conference and Expo

We are delighted to announce that Nanomerics’ Chief Executive Officer (CEO), Professor Andreas Schätzlein will be presenting a paper at the iPharma 3rd Global Pharmaceutical Conference and Expo in London, UK on the 3rd and 4th July 2019.  Professor Schätzlein will discuss "The Molecular Envelope Technology (MET) Platform - Engineering for Delivery" on Thursday 4th of July 2019.  If you wish to meet with Nanomerics' CEO please get in touch.

June 2019

RSC logo

Nanomerics’ Chief Scientific Officer to present at the Royal Society of Chemistry’s Formula X meeting in Manchester, UK

We are delighted to announce that Nanomerics’ Chief Scientific Officer (CSO), Professor Ijeoma F. Uchegbu will be presenting a paper at the Royal Society of Chemistry’s Formula X conference which will take place at the University of Manchester from the 24th - 27th of June 2019.  Professor Uchegbu will be presenting a paper on the 25th of June 2019.   If you wish to meet with Nanomerics' CSO on the 25th of June, please get in touch.

May 2019

Nanomerics presenting at EPM Drug Delivery and Formulation Munich

Nanomerics are pleased to announce that Professor Ijeoma F. Uchegbu, Nanomerics’ Chief Scientific Officer (CSO), will be presenting on Nanomerics' award winning Molecular Envelop Technology at EPM’s Drug Delivery and Formulation Conference in Munich on the 20th of September 2019.  If you wish to meet with Nanomerics’ CSO in Munich, please get in touch and we will arrange a meeting.  

April 2019

February 2019

Nanomerics announces new US and Japan patents

Nanomerics is pleased to announce the imminent publication of key patents underpinning its NM127 asset. Nanomerics has been notified by the US Patent and Trademark Office of the imminent publication of US10213474 on the 26th of February.  This key patent further strengthens Nanomerics patent portfolio and enables Nanomerics to continue the development of NM127.  Nanomerics is also pleased to announce a notice of allowance issued by the Japanese Intellectual Property Office for application JP2016-526933.

December 2018

Nanomerics wins Innovate UK grant to progress development of NM127 pain therapeutic

Today Nanomerics announced the award of a research grant from Innovate UK.  The award has been made to progress the development of NM127, Nanomerics’ pain asset.  The award will fund a collaboration between Nanomerics Ltd.  and Alchemy Pharmatech Ltd. and will involve the coupling of Alchemy Pharmatech’s Naltos nasal delivery device with Nanomerics’ enkephalin based formulation for the treatment of breakthrough, neuropathic and post operative pain.

October 2018

September 2018

Nanomerics Announces New Canadian Patent Underpinning its Enkephalin Assets Proceeding to Grant

Nanomerics today announced that the Canadian Intellectual Property Office will allow key patent application underpinning its enkephalin pain therapeutic (patent application number - CA2754140) to proceed to grant.   This patent supports Nanomerics’ pain therapeutics, including NM0127 and provides further assurances to potential partners on patent protection in key markets.  Nanomerics will continue to defend its assets with key patent applications and ongoing patent prosecution.  This is a major component of its business strategy.